MedPath

Oculus Innovative Sciences Inc

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:2

Trial Phases

2 Phases

Phase 2:2
Not Applicable:1

Drug Approvals

3

FDA:3

Drug Approvals

Deltasone

Approval Date
Nov 7, 2017
FDA

Mondoxyne NL 100mg

Approval Date
Sep 11, 2015
FDA

Mondoxyne

Approval Date
Sep 2, 2015
FDA

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (66.7%)
Not Applicable
1 (33.3%)

A Substantial Equivalence Study of RD04723 and Predicate Device

Not Applicable
Conditions
Hypertrophic Scar
Keloid Scar
First Posted Date
2012-11-29
Last Posted Date
2012-12-03
Lead Sponsor
Oculus Innovative Sciences, Inc.
Target Recruit Count
40
Registration Number
NCT01736969
Locations
🇺🇸

DermResearch Inc, Austin, Texas, United States

Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults

Phase 2
Completed
Conditions
Atopic Dermatitis
Pruritus
First Posted Date
2010-11-02
Last Posted Date
2012-05-30
Lead Sponsor
Oculus Innovative Sciences, Inc.
Target Recruit Count
17
Registration Number
NCT01232985
Locations
🇺🇸

Dermatology Consulting Services, High Point, North Carolina, United States

Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care to Treat Mild Diabetic Foot Infections

Phase 2
Completed
Conditions
Foot Ulcer, Diabetic
Interventions
Drug: Topical Saline and Levofloxacin
Drug: Topical Dermacyn
Drug: Topical Dermacyn and Levofloxacin
First Posted Date
2007-08-16
Last Posted Date
2008-01-14
Lead Sponsor
Oculus Innovative Sciences, Inc.
Target Recruit Count
65
Registration Number
NCT00516958

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.